Improvement of the verification of liver fibrosis using new minimally invasive markers in patients with metabolic-associated steatotic liver disease

Background.Improvement of the verification of earlystage liver fibrosis using new minimally invasive markers in patients with metabolic-associated steatotic liver disease (MASLD) is a topical issue today.Aim.To identify new minimally invasive serum markers of fibrotic liver chan ges in patients with MASLD and compare them with wellknown fibrosis diagnostic indices.Methods.We examined 108 patients with MASLD with a mean age of (48,01,84), of whom 84 were without fibrosis and 24 had fibrosis that was confirmed morphologically.The concentration of TNF-, IL-10, insulin, and 1-acid glycopeptide in the blood serum was determined by ELISA, and the activity of enzymes (ALT, AST, GGTP, ALP), hemostatic system, lipid, carbohydrate, and protein metabolism in the blood were measured to calculate fibrosis indices: Forns index, APRI, FIB-4 AAR.Correlation analysis was performed according to Spearman (r), and ROC analysis was used to assess the diagnostic efficiency of the indicators with the determination of the area under the ROC curve (AUC) and its 95% confidence interval (CI) to determine the quality and reliability of the diagnostic model (p).Results.In patients with MASLD, the liver stiffness was found to be in a direct correlation with the HOMA-IR index (r = 0.710; p < 0.05), which was 1.7 times higher in the patients with liver fibrosis than without fibrosis.A direct correlation was found between the liver stiffness index and 1-acid glycopeptide (r = 0.693; p < 0.05), which was 1.4 times (p < 0.05) higher in patients with liver fibrosis than without fibrosis, and with the TNF/IL-10 ratio (r = 0.637; p < 0.05), which